NCT01049165View on ClinicalTrials.gov

Single Ascending Dose (BMS-813160) Study

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Accelerated Intimal Hyperplasia
Interventions
DRUG

BMS-813160

Oral Solution, Oral, 5 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 20 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 60 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 150 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 300 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 600 mg, Single Dose, 1 day

DRUG

[14C] BMS-813160

Oral Solution, Oral, 150 mg, Single Dose, 1 day

DRUG

Placebo

Oral Solution, Oral, 0 mg, Single Dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 1200 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 2000 mg, Single Dose, 1 day

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY